Chad Gassert Sells 14,642 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Chad Gassert sold 14,642 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $89.07, for a total value of $1,304,162.94. Following the completion of the transaction, the senior vice president directly owned 158,584 shares in the company, valued at approximately $14,125,076.88. This represents a 8.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Chad Gassert also recently made the following trade(s):

• On Thursday, November 13th, Chad Gassert sold 94 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $88.00, for a total transaction of $8,272.00.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $84.02 on Friday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. The company’s fifty day moving average price is $92.77 and its 200-day moving average price is $78.18. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $99.50. The company has a market capitalization of $1.82 billion, a PE ratio of -109.12 and a beta of 0.54.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The company had revenue of $227.81 million for the quarter, compared to the consensus estimate of $211.92 million. During the same period in the previous year, the firm posted $1.34 EPS. ANI Pharmaceuticals’s revenue for the quarter was up 53.6% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC boosted its stake in shares of ANI Pharmaceuticals by 9.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,505 shares of the specialty pharmaceutical company’s stock worth $138,000 after purchasing an additional 126 shares during the period. Illinois Municipal Retirement Fund lifted its stake in ANI Pharmaceuticals by 1.7% in the third quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company’s stock worth $782,000 after purchasing an additional 145 shares during the last quarter. Amalgamated Bank boosted its position in shares of ANI Pharmaceuticals by 3.1% during the third quarter. Amalgamated Bank now owns 5,066 shares of the specialty pharmaceutical company’s stock valued at $464,000 after buying an additional 154 shares during the period. CANADA LIFE ASSURANCE Co boosted its position in shares of ANI Pharmaceuticals by 1.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after buying an additional 198 shares during the period. Finally, Hantz Financial Services Inc. grew its stake in shares of ANI Pharmaceuticals by 202.6% during the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after buying an additional 237 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on ANIP shares. HC Wainwright raised their price target on ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Piper Sandler reissued an “overweight” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Weiss Ratings upgraded shares of ANI Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a research report on Monday, November 10th. JPMorgan Chase & Co. increased their price objective on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, September 24th. Finally, Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $99.29.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.